On June 13th, Gelonghui reported that Moderna announced that the Phase III trial of its next-generation COVID-19 vaccine has achieved its primary goals and demonstrated higher efficacy than the Spikevax vaccine in adults aged 18 and above.
Moderna公布下一代COVID-19候选疫苗积极试验结果
Moderna has announced positive trial results for its next generation COVID-19 vaccine candidate.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.